Priority 1 from the Autosomal Dominant Polycystic Kidney Disease Project

UNCERTAINTY: What treatments can be developed that slow or prevent progression of ADPKD and improve patients’ quality of life? (Priority 1)
Overall ranking	1
JLA question ID	0103/1
Explanatory note	Not available for this PSP
Evidence	Thida M Myint Gopi K Rangan Angela C Webster (2014) Treatments to slow progression of autosomal dominant polycystic kidney disease: systematic review and meta‐analysis of randomized trials. https://doi.org/10.1111/nep.12211
Health Research Classification System category	Renal and urogenital

Extra information provided by this project
Original uncertainty examples	Development of disease-modifying treatments for ADPKD with the potential to maintain quality of life, delay renal decline and improve life expectancy among patients, and to reduce the economic impact on healthcare systems. ~ Development of new treatments to delay the progression of ADPKD. ~ What are the benefits of therapeutic, lifestyle and dietary interventions for people with ADPKD?
Submitted by	2 x research recommendation and Kidney Disease Improving Global Outcomes (KDIGO)

Project information
Project unique ID	0103
Project name	Autosomal Dominant Polycystic Kidney Disease
Total number of uncertainties identified by this project.	35 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop	15 December 2020